Clinical performance of six different serum tartrate-resistant acid phosphatase assays for monitoring alendronate treatment

Clinical Laboratory

Volumn 54, Issue 9-10, 2008, Pages 347-354

  Fagerlund, Katja M ^a   Janckila, Anthony J ^b   Ylipahkala, Hannele ^a   Tiitinen, Sari L ^c   Nenonen, Arja ^d   Cheng, Sulin ^e   Uusi Rasi, Kirsti ^f   Yam, Lung T ^b   Väänänen, H Kalervo ^a   Halleen, Jussi M ^g  

^a UNIVERSITY OF TURKU   (Finland)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Finnish Red Cross   (Finland)

^d RHEUMATISM FOUNDATION HOSPITAL   (Finland)

^e UNIVERSITY OF JYVÄSKYLÄ   (Finland)

^f UKK INSTITUTE FOR HEALTH PROMOTION RESEARCH   (Finland)

^g Pharmatest Services Ltd   (Finland)

Author keywords

Alendronate treatment; Immunoassay; TRACP 5a; TRACP 5b

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME 5A; ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME 5B; ALENDRONIC ACID; PLACEBO; UNCLASSIFIED DRUG;

ARTICLE; BONE TURNOVER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG ACTIVITY; DRUG MONITORING; DRUG RESPONSE; ENZYME BLOOD LEVEL; FEMALE; HUMAN; IMMUNOASSAY; OSTEOLYSIS; PH; PROTEIN CONTENT; SOLVENT EFFECT; TREATMENT DURATION;

ACID PHOSPHATASE; ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; DRUG MONITORING; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; ISOENZYMES; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; ROC CURVE;

EID: 57149106133     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Halleen JM, Tiitinen SL, Ylipahkala H, Fagerlund KM, Väädnänen HK. Tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of bone resorption. Clin Lab 2006;52:499-509.
2. Janckila AJ, Parthasarathy RN, Parthasarathy LK, Seelan RS, Yam LT. Stable expression of human tartrate-resistant acid phosphatase isoforms by CHO cells. Clin Chim Acta 2002;326: 113-22.
3. Janckila AJ, Parthasarathy RN, Parthasarathy LK, et al. Properties and expression of human tartrate-resistant acid phosphatase isoform 5a by monocyte-derived cells. J Leukoc Biol 2005;77: 209-18.
4. Lam KW, Siemens M, Sun T, Li CY, Yam LT. Enzyme immunoassay for tartrate-resistant acid phosphatase. Clin Chem 1982;28:467-70.
5. Echetebu ZO, Cox TM, Moss DW. Antibodies to porcine uteroferrin used in measurement of human tartrate-resistant acid phosphatase. Clin Chem 1987;33:1832-6.
6. Nakasato YR, Janckila AJ, Halleen JM, Väänänen HY, Walton SP, Yam LT. Clinical significance of immunoassays for type-5 tartrate-resistant acid phosphatase. Clin Chem 1999;45:2150-7.
7. Miyazaki S, Igarashi M, Nagata A, Tominaga Y, Onodera K, Komoda T. Development of immunoassays for type-5 tartrate-resistant acid phosphatase in human serum. Clin Chim Acta 2003;329:109-15.
8. Kraenzlin ME, Lau KH, Liang L, et al. Development of an immunoassay for human serum osteoclastic tartrate-resistant acid phosphatase. J Clin Endocrinol Metab 1990;71:442-51.
9. Chamberlain P, Compston J, Cox TM, et al. Generation and characterization of monoclonal antibodies to human type-5 tartrate-resistant acid phosphatase: development of a specific immunoassay of the isoenzyme in serum. Clin Chem 1995;41: 1495-9.
10. Cheung CK, Panesar NS, Haines C, Masarei J, Swaminathan R. Immunuassay of a tartrate-resistant acid phosphatase in serum. Clin Chem 1995;41:679-86.
11. Halleen JM, Hentunen TA, Hellman J, Vadridnen HK. Tartrate-resistant acid phosphatase from human bone and development of an immunoassay. J Bone Miner Res 1996; 11: 1444-1452.
12. Halleen JM, Hentunen TA, Karp M, Käkönen SM, Pettersson K, Väänänen HK. Characterization of serum tartrate-resistant acid phosphatase and development of a direct two-site immunoassay. J Bone Miner Res 1998;13:683-7.
13. Chao TY, Lee SH, Chen MM, et al. Development of immunoassays for serum tartrate-resistant acid phosphatase isoform 5a. Clin Chim Acta 2005;359:132-40.
14. Janckila AJ, Simons RM, Yam LT. Alternative immunoassay for tartrate-resistant acid phosphatase isoform 5b using the fluorogenic substrate naphthol ASBI-phosphate and heparin. Clin Chim Acta 2004;347:157-67.
15. Halleen JM, Alatalo SL, Suominen H, Cheng S, Janckila AJ, Väänänen HK. Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption. J Bone Miner Res 2000;15: 1337-45.
16. Nakanishi M, Yoh K, Miura T, Ohasi T, Rai SK, Uchida K. Development of a kinetic assay for band 5b tartrate-resistant acid phosphatase activity in serum. Clin Chem 2000;46:469-73.
17. Ohashi T, Igarashi Y, Mochizuki Y, et al. Development of a novel fragments absorbed immunocapture enzyme assay system for tartrate-resistant acid phosphatase 5b. Clin Chim Acta 2007; 376:205-12.
18. Janckila AJ, Takahashi K, Sun SZ, Yam LT. Naphthol-ASBI phosphate as a preferred substrate for tartrate-resistant acid phosphatase isoform 5b. J Bone Miner Res 2001;16:788-93.
19. Janckila AJ, Neustadt DH, Nakasato YR, Halleen JM, Hentunen T, Yam LT. Serum tartrate-resistant acid phosphatase isoforms in rheumatoid arthritis. Clin Chim Acta 2002;320:49-58.
20. Alakangas A, Selander K, Mulari M, et al. Alendronate disturbs vesicular trafficking in osteoclasts. Calcif Tissue Int 2002;70: 40-7.
21. Hannon RA, Clowes JA, Eagleton AC, Al Hadari A, Eastell R, Blumsohn A. Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorption. Bone 2004;34:187-94.
22. Nenonen A, Cheng S, Ivaska KK, et al. Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover. J Bone Miner Res 2005;20: 1804-12.
23. Uusi-Rasi K, Kannus P, Cheng S, et al. Effect of alendronate and exercise on bone and physical performance of postmenopausal women: a randomized controlled trial. Bone 2003;33: 132-43.
24. Sievänen H, Kannus P, Nieminen V, Heinonen A, Oja P, Vuori I. Estimation of various mechanical characteristics of human bones using dual energy X-ray absorptiometry: methodology and precision. Bone 1996;18:17S-27S.
25. Janckila AJ, Takahashi K, Sun SZ, Yam LT. Tartrate-resistant acid phosphatase isoform 5b as serum marker for osteoclastic activity. Clin Chem 2001;47:74-90.
26. Halleen JM, Ylipahkala H, Alatalo SL, et al. Serum tartrate-resistant acid phosphatase 5b, but not 5a, correlates with other markers of bone turnover and bone mineral density. Calcif Tissue Int 2002;71:20-5.
27. Ljusberg J, Ek-Rylander B, Andersson G. Tartrate-resistant purple acid phosphatase is synthesized as a latent proenzyme and activated by cysteine proteinases. Biochem J 1999;343 Pt 1: 63-9.
28. Li CY, Chuda RA, Lam WW, Yam LT. Acid phosphatases in human plasma. J Lab Clin Med 1973;82:446-60.